To examine evidence of positive antibodies against immunogenic proteins of Anaplasma phagocytophilum in patients with other tick-borne infections and to diagnose possible co-infections, 412 serum specimens were tested by immunoblotting using three specific Anaplasma antigens: surface proteins p44 and Asp62 and outer membrane protein A (OmpA). In total, 284 serum samples from children with Lyme borreliosis and 12 serum samples from children with tick-borne encephalitis were tested. Sera from patients with viral aseptic meningitis (n = 47) and from blood donors (n = 69) were used as controls. Among all serum specimens from patients with tick-borne infections submitted for this study, six samples (2·0%) showed positive IgM reactions and seven samples (2·4%) were IgG positive for A. phagocytophilum by immunoblot. Borderline reactivity was found in 30 samples (10·14%) for IgM and 36 samples (12·2%) for IgG. The difference between patients and blood donors was statistically significant for IgM (P = 0·006) and for IgG (P = 0·0007) antibodies. A statistically significant result was obtained for IgG (P = 0·02) but not for IgM between patients and children with aseptic meningitis. Immunoblot using three specific antigens provides novel information about the positivity of antibodies to A. phagocytophilum in children with other tick-borne infections. Taking into account clinical and laboratory findings of children despite antibody positivity, no case of human granulocytic anaplasmosis was demonstrated.

Department of Children's Infectious Diseases Faculty of Medicine and University Hospital Masaryk University Brno Czech Republic

Department of Clinical Biochemistry University Hospital Brno Department of Laboratory Methods Faculty of Medicine Masaryk University Brno Czech Republic

Department of Clinical Microbiology University Hospital Brno Czech Republic

Zobrazit více v PubMed

Chen S, et al. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. Journal of Clinical Microbiology 1994; 32: 589. PubMed PMC

Adams DA, et al. Reports of nationally notifiable infectious diseases – United States, 2011. Morbidity and Mortality Weekly Report 2013; 60: 1–117. PubMed

Blanco JR, Oteo JA. Human granulocytic ehrlichiosis in Europe. Clinical Microbiology and Infection 2002; 8: 763–772. PubMed

Petrovec M, et al. Human disease in Europe caused by a granulocytic Ehrlichia species. Journal of Clinical Microbiology 1997; 35: 1556–1559. PubMed PMC

Arnež M, et al. First European pediatric case of human granulocytic ehrlichiosis. Journal of Clinical Microbiology 2001; 39: 4591–4592. PubMed PMC

Bakken JS, et al. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. Journal of the American Medical Association 1996; 275: 199–205. PubMed

Lotric-Furlan S, et al. Human granulocytic ehrlichiosis in Europe: clinical and laboratory findings for four patients from Slovenia. Clinical Infectious Diseases 1998; 27: 424–428. PubMed

Heo E, et al. Serologic and molecular detection of Ehrlichia chaffeensis and Anaplasma phagocytophila (human granulocytic ehrlichiosis agent) in Korean patients. Journal of Clinical Microbiology 2002; 40: 3082–3085. PubMed PMC

Park J, et al. Detection of antibodies to Anaplasma phagocytophilum and Ehrlichia chaffeensis antigens in sera of Korean patients by Western immunoblotting and indirect immunofluorescence assays. Clinical and Diagnostic Laboratory Immunology 2003; 10: 1059–1064. PubMed PMC

Ge Y, Rikihisa Y. Identification of novel surface proteins of Anaplasma phagocytophilum by affinity purification and proteomics. Journal of Bacteriology 2007; 189: 7819–7828. PubMed PMC

Ojogun N, et al. Anaplasma phagocytophilum outer membrane protein A interacts with sialylated glycoproteins to promote infection of mammalian host cells. Infection and Immunity 2012; 80: 3748–3760. PubMed PMC

Mygland A, et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. European Journal of Neurology 2010; 17: 8–16. PubMed

Stanek G, et al. Lyme borreliosis: clinical case definition for diagnosis and management in Europe. Clinical Microbiology and Infection 2011; 17: 79–79. PubMed

Oteo JA, et al. Presence of granulocytic ehrlichia in ticks and serological evidence of human infection in La Rioja, Spain. Epidemiology and Infection 2001; 127: 353–358. PubMed PMC

Cizman M, et al. Seroprevalence of ehrlichiosis, Lyme borreliosis and tick-borne encephalitis infections in children and young adults in Slovenia. Wiener Klinische Wochenschrift 2000; 112: 842–845. PubMed

Cinco M, et al. Detection of HGE agent-like Ehrlichia in Ixodes ricinus ticks in northern Italy by PCR. Wiener Klinische Wochenschrift 1998; 110: 898–900. PubMed

Jenkins A, et al. Borrelia burgdorferi sensu lato and Ehrlichia sp. in Ixodes ticks from southern Norway. Journal of Clinical Microbiology 2001; 39: 3666–3671. PubMed PMC

Lebech AM, et al. Immunoserologic evidence of human granulocytic ehrlichiosis in Danish patients with Lyme neuroborreliosis. Scandinavian Journal of Infectious Diseases 1998; 30: 173–176. PubMed

Zeman P, et al. Antibodies to granulocytic Ehrlichiae in the population of the western and central part of the Czech Republic [in Czech, English abstract available]. Epidemiologie, Mikrobiologie, Imunologie 2002; 51: 13–18. PubMed

Dvořáková Heroldová M, Dvořáčková M. Seroprevalence of Anaplasma phagocytophilum in patients with suspected Lyme borreliosis [in Czech, English abstract available]. Epidemiologie, Mikrobiologie, Imunologie 2014; 63: 297–302. PubMed

Hulínská D, et al. Detection of Borrelia, Anaplasma, Bartonella and Rickettsia spp. in ticks Ixodes ricinus from Prague parks in 2007 and 2008 [in Czech, English abstract available]. Zprávy Centra Epidemiologie a Mikrobiologie 2009; 18: 167–171.

Wormser GP, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis and babesiosis: clinical practice guidelines by the Infectious Disease Society of America. Clinical Infectious Diseases 2006; 43: 1089–1134. PubMed

Steere AC, et al. Prospective study of serologic tests for Lyme disease. Clinical Infectious Diseases 2008; 47: 188–195. PubMed PMC

DeBiasi RL. A concise critical analysis of serologic testing for the diagnosis of Lyme disease. Current Infectious Disease Reports 2014; 16: 450. PubMed

Lotrič-Furlan S, et al. Epidemiological, clinical and laboratory distinction between human granulocytic ehrlichiosis and the initial phase of tick-borne encephalitis. Wiener Klinische Wochenschrift 2002; 114: 636–640. PubMed

Fingerle V, et al. Human granulocytic ehrlichiosis in Southern Germany: increased seroprevalence in high-risk group. Journal of Clinical Microbiology 1997; 35: 3244–3247. PubMed PMC

Pusterla N, et al. Serological evidence of human granulocytic ehrlichiosis in Switzerland. European Journal of Clinical Microbiology and Infectious Diseases 1998; 17: 207–209. PubMed

Unver A, et al. Western blot analysis of sera reactive to human monocytic ehrlichiosis and human granulocytic ehrlichiosis agents. Journal of Clinical Microbiology 2001; 39: 3982–3986. PubMed PMC

Wormser GP, et al. Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic ehrlichiosis. American Journal of Clinical Pathology 1997; 107: 142–147. PubMed

Horowitz HW, et al. Lyme disease and human granulocytic anaplasmosis coinfection: impact of case definition on coinfection rates and illness severity. Clinical Infectious Diseases 2013; 56: 93–99. PubMed